Study your flashcards anywhere!

Download the official Cram app for free >

  • Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key


Play button


Play button




Click to flip

6 Cards in this Set

  • Front
  • Back
Vaccine components: Combination of diphtheria and tetanus toxoids with inactivated pertussis antigens
Clinical efficacy: Diphtheria toxoid 95%, Tetanus toxoid 100%, Pertussis 85%
Given IM at 2, 4, 6, 15-18 months, and 4-6 years
Tdap booster at 11-12 years
Side Effects of DTaP
Local and febrile reactions
1 child in 4
Fever, fussiness, decreased appetite
High fever - 1 in 16,000
Allergic reactions
Severe – very rare (estimated 1 per 1 million doses)
1 child in 14,000
Contraindications for DTaP
Anaphylactic reaction
Encephalopathy within 7 days of vaccine
High fever, crying>3 hours, seizures within 3 days and collapse-like state within 48 hours
Children with neurologic disorders
Must be individually evaluated for suitability
Non-progressive vs. progressive disorder
IPV and OPV (Polio Vaccines)
Vaccine component
Trivalent inactivated polio vaccine (virus types 1, 2 & 3)
Clinical efficacy
High seroconversion rates, poor gut immunity (vs. OPV)
Given by SQ or IM injection at 2 and 4 months, 6-18 months, and 4-6 years
In endemic areas, OPV preferred for ease of administration and added barrier of intestinal mucosal immunity to interrupt transmission
Side Effects & Contraindications of IPV
Side Effects
Local reactions
Severe allergic reaction (very rare)
Previous anaphylactic reaction to the vaccine or a vaccine component (neomycin, streptomycin, polymyxin B)
Defer vaccine if moderately or severely ill
Hib (Haemophilus influenzae type B) vaccine
Vaccine components
Type b capsular polysaccharide conjugated with a protein antigen to maximize immunogenicity
Clinical efficacy
Given at 2 and 4 months (or 2, 4, and 6 months depending on the vaccine formulation) with a booster at 12-15 months
If child had invasive H. flu disease before age 2, must restart entire vaccine series